Unknown

Dataset Information

0

An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.


ABSTRACT: Background C3 glomerulopathy (C3G) is associated with dysregulation of the alternative pathway of complement activation, and treatment options for C3G remain limited. Complement factor H (FH) is a potent regulator of the alternative pathway and might offer a solution, but the mass and complexity of FH makes generation of full-length FH far from trivial. We previously generated a mini-FH construct, with FH short consensus repeats 1-5 linked to repeats 18-20 (FH1-5^18-20), that was effective in experimental C3G. However, the serum t1/2 of FH1-5^18-20 was significantly shorter than that of serum-purified FH.Methods We introduced the oligomerization domain of human FH-related protein 1 (denoted by R1-2) at the carboxy or amino terminus of human FH1-5^18-20 to generate two homodimeric mini-FH constructs (FHR1-2^1-5^18-20 and FH1-5^18-20^R1-2, respectively) in Chinese hamster ovary cells and tested these constructs using binding, fluid-phase, and erythrocyte lysis assays, followed by experiments in FH-deficient Cfh-/- mice.Results FHR1-2^1-5^18-20 and FH1-5^18-20^R1-2 homodimerized in solution and displayed avid binding profiles on clustered C3b surfaces, particularly FHR1-2^1-5^18-20 Each construct was >10-fold more effective than FH at inhibiting cell surface complement activity in vitro and restricted glomerular basement membrane C3 deposition in vivo significantly better than FH or FH1-5^18-20 FH1-5^18-20^R1-2 had a C3 breakdown fragment binding profile similar to that of FH, a >5-fold increase in serum t1/2 compared with that of FH1-5^18-20, and significantly better retention in the kidney than FH or FH1-5^18-20Conclusions FH1-5^18-20^R1-2 may have utility as a treatment option for C3G or other complement-mediated diseases.

SUBMITTER: Yang Y 

PROVIDER: S-EPMC6054357 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Yang Yi Y   Denton Harriet H   Davies Owen R OR   Smith-Jackson Kate K   Kerr Heather H   Herbert Andrew P AP   Barlow Paul N PN   Pickering Matthew C MC   Marchbank Kevin J KJ  

Journal of the American Society of Nephrology : JASN 20180327 6


<b>Background</b> C3 glomerulopathy (C3G) is associated with dysregulation of the alternative pathway of complement activation, and treatment options for C3G remain limited. Complement factor H (FH) is a potent regulator of the alternative pathway and might offer a solution, but the mass and complexity of FH makes generation of full-length FH far from trivial. We previously generated a mini-FH construct, with FH short consensus repeats 1-5 linked to repeats 18-20 (FH<sup>1-5^18-20</sup>), that w  ...[more]

Similar Datasets

| S-EPMC4650264 | biostudies-literature
| S-EPMC4220750 | biostudies-literature
| S-EPMC10927479 | biostudies-literature
| S-EPMC4731119 | biostudies-literature
| S-EPMC7253029 | biostudies-literature
| S-EPMC4849824 | biostudies-other
| S-EPMC4869622 | biostudies-literature
| S-EPMC3668852 | biostudies-literature
| S-EPMC3810083 | biostudies-other
| S-EPMC6829196 | biostudies-literature